AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01878578
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing matching placebo
Trial: NCT02860234
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01110525
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4X100 mg per oral, twice daily for 28 days
Trial: NCT01110525
Drug: Neovletta 21/28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily with (21) or without (28) pause for bleeding.
Trial: NCT01110525
Drug: Placebo AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4X100 mg per oral, twice daily for 28 days
Trial: NCT03028129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, without the active ingredient, similar in size, weight, color, taste and odor.
Trial: NCT00683930
Drug: Mycophenolate Mofetil 2 g/Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
Trial: NCT00683930
Drug: Mycophenolate Mofetil (MMF) 3 g/Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
Trial: NCT00683930
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for MMF 2 g/day group: 4 tablets orally twice daily for 52 weeks; placebo for MMF 3 g/day group: 6 tablets orally twice daily for 52 weeks
Trial: NCT00913887
Drug: Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)
RxNorm normalized name: diclofenac sodium 75 MG
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00913887
Drug: Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)
RxNorm normalized name: diclofenac sodium 75 MG
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00913887
Drug: Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02993822
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, once daily, oral
Trial: NCT02094378
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intranasally
Trial: NCT01158820
Drug: Fentanyl load
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 µg bolus prior to bronchoscopy
Trial: NCT01158820
Drug: Fentanyl demand
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12.5 µg demand bolus at discretion of pulmonologist
Trial: NCT01158820
Drug: Benadryl demand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus
Trial: NCT01849692
Drug: ESBA1008 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection or infusion
Trial: NCT01262560
Drug: Standard supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive standard supporting care for esophagitis-related pain as needed during concurrent chemotherapy and radiation treatment. The following regimen is recommended, but the local standard of care is permitted.~1. A compound containing viscous lidocaine and magnesium aluminum oxide (Maalox®);~2. Liquid or solid oxycodone, 5-10 mg, every 3 hours as needed.
Trial: NCT01814046
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
Trial: NCT02774993
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04382586
Drug: Supportive Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care treatment was selected and administered as deemed appropriate by the study investigator
Trial: NCT04382586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match zanubrutinib
Trial: NCT00648388
Drug: Pletal® Tablets 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 single dose fasting
Trial: NCT01039545
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac retard 75mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
Trial: NCT00555607
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone oral tablets (10 mg active ingredient per tablet) once a day at a dose of 0.5mg/kg bodyweight, during 14 days.
Trial: NCT02789436
Drug: L. reuteri Prodentis® lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily, for 28 days
Trial: NCT03192293
Drug: Metformin/Simvastatin/Fulvestrant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days Lead-in period: Metformin: 850mg (one tablet) twice a day Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle.~Tumour biopsy at 8 weeks. Every 8 weeks for the first 6 months, every 12 weeks thereafter:~Performance status evaluation Medical history and physical examination Clinical tumor measurement Review of treatment-related side-effects Blood taking for research purpose and routine blood tests Routine scans
Trial: NCT01974206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular injection
Trial: NCT01063062
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate as per standard of care in clinical practice.
Trial: NCT02434549
Drug: Dysport®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections in spastic muscle with regional muscle-related pain
Trial: NCT02434549
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections in spastic muscle with regional muscle-related pain
Trial: NCT01762774
Drug: GSK2256294
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.
Trial: NCT01762774
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).
Trial: NCT00046293
Drug: Retrovase
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00335283
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet bid
Trial: NCT02707965
Drug: Oxcarbazepine (brand name vs generic drugs)
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
Trial: NCT02707965
Drug: Phenytoin sodium (brand name vs generic drugs)
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
Trial: NCT01951586
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
Trial: NCT01951586
Drug: Standard Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.
Trial: NCT01951586
Drug: Placebo to Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
Trial: NCT02944708
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03850093
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients received oral placebo 2 hrs preoperative
Trial: NCT01111604
Drug: mFOLFOX-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin: 85 milligram per square meter (mg/m²) IV every 2 weeks (Q2W)~FA: 400 mg/m² IV Q2W (or LFA: 200 mg/m² Q2W if FA is unavailable).~5FU: 400 mg/m² bolus + 2400 mg/m² IV Q2W
Trial: NCT01703091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT03815695
Drug: FT-4202/Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
Trial: NCT02384499
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline with fibrin glue injection to the anal sphincter of patients with fecal incontinence
Trial: NCT04075513
Drug: Background therapy: Rapid acting insulin analogs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of administration: SC injection
Trial: NCT01003236
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 mg placebo tablets, 3 times per day for 3 months
Trial: NCT02384473
Drug: Definity Suspension for Injection
RxNorm normalized name: Definity Suspension for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will receive contrast agent by intravenous administration
Trial: NCT03312140
Drug: Choline Chloride
RxNorm normalized name: Choline Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03467893
Drug: Antacids
RxNorm normalized name: ANTACIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: number aof antacids treatment after PPI stop
Trial: NCT05366621
Drug: Anti-osteoporosis medications
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication exposure was defined as the usage of osteoporosis medications approved by the Taiwan Food and Drug Administration (TFDA), including alendronate, risedronate, ibandronate, zoledronic acid, denosumab, raloxifene, bazedoxifene, calcitonin, and teriparatide, but excluded patients using the osteoporosis medication for cancer-related treatments (such as high dosing frequency of zoledronic acid or denosumab).
Trial: NCT00614445
Drug: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: up to 4 tablets daily, titrated according to the protocol
Trial: NCT00614445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 to 4 tablets daily titrated according to the protocol
Trial: NCT01812213
Drug: [18F]NAV4694
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05378711
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children will receive a placebo or fluoxetine at different times dependent upon random assignment to a treatment schedule.
Trial: NCT03263910
Drug: NPO-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml NPO-11
Trial: NCT03263910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml NPO-11(Placebo)
Trial: NCT02817789
Drug: Combination lysine acetylsalicylate - clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg before and 75 mg daily after the procedure of lysine acetylsalicylate and 300mg loading dose before and 75 mg of clopidogrel daily after the procedure
Trial: NCT03319459
Drug: FATE-NK100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity
Trial: NCT04444986
Drug: AVIGAN 200 mg FT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVIGAN containing 200 mg favipiravir manufactured by Toyama, Japan
Trial: NCT04094493
Drug: vit D
RxNorm normalized name: Tri-Vit Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preoperative intra muscular vit D injection
Trial: NCT02414945
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01111383
Drug: tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300mg/4ml solution, via a nebuliser, over a 48-week period in a twice-daily regimen, with 6 on cycles of 4 weeks duration during the 48-week period.
Trial: NCT00684710
Drug: PAZ-417
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00684710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01375816
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01375816
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01009970
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 day 2
Trial: NCT01009970
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 day 2
Trial: NCT00080743
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One pill po once daily
Trial: NCT00003352
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, IV, every 3 weeks
Trial: NCT03680196
Drug: medication Botulinum A injection.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In cerebral palsy patients, Botulinum toxin within the allowable dose of 16 U / kg per body weight will injected into both adductor longus, adductor magnus muscle at 3 U / kg, adductor brevis, and gracilis muscle at a dose of 1 U / kg.
Trial: NCT00918515
Drug: AZD3043
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous solution given once as intravenous infusion over 30 minutes
Trial: NCT03095456
Drug: Placebo for Spiriva Handihaler®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as double blind, double dummy via Spiriva HandiHaler®.
Trial: NCT01971853
Drug: oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen placebo and Acetaminophen placebo will be added to a Demerol-Vistaril regimen
Trial: NCT00987116
Drug: Prednisone - Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rapid strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for improvement or minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 0.75 mg/kg/day.~Classical strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 1.5 mg/kg/2days.
Trial: NCT04470050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual Placebo film
Trial: NCT03972462
Drug: NPC-12G Gel 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1
Trial: NCT03972462
Drug: Rapamune® 2 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 2
Trial: NCT02375191
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01104545
Drug: MK-3614
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01104545
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02057640
Drug: MLN9708
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4mg on day 1, 8, 15, 28
Trial: NCT00628433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02128191
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of 10 mg/kg of oral ibuprofen, followed by two doses of 5 mg/kg 24 and 48 hours later
Trial: NCT02128191
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
Trial: NCT02209792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02209792
Drug: BIBR 796 BS, 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02209792
Drug: BIBR 796 BS, 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04107740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID, 10mg per day, for 24 weeks
Trial: NCT00669812
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00669812
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00669812
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00669812
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03265197
Drug: Intra-tympanic injection of drugs
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
Trial: NCT02073279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
Trial: NCT00853554
Drug: Dilaudid® tablet 8 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilaudid® tablet 8 mg, single dose fasting
Trial: NCT01964495
Drug: Discontinuation of treatment according to CRP levels
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The cutoff point is a CRP below 100 mg/L and a reduction to 50% of the initial value.
Trial: NCT01964495
Drug: Discontinuation of treatment according to PCT levels
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The cutoff point is a PCT below 0.25 mcg/L or a reduction to 10% of the initial value.
Trial: NCT01964495
Drug: Treatment according to current guidelines
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Often a 7 days course of antibiotics, treatment may be extended if the attending physician deems it necessary.
Trial: NCT01006655
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation twice a day for one month, preceded and followed by adenosine challenge test
Trial: NCT01267864
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30g IVSS
Trial: NCT02599753
Drug: 18-FDTBZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During this study, participants will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on the investigators' phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010).
Trial: NCT00395486
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg
Trial: NCT01606176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each actuation of placebo (100 μl) delivered the excipients only. The maximum permitted dose of study medication was eight actuations in any three hour period and 48 actuations in any 24 hour period.
Trial: NCT02443246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01391481
Drug: Perfluorocarbon
RxNorm normalized name: HYDROFLUOROCARBON 227EA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaporized PFC Inhalation 100ml/8h for 5 days